
ESLA Stock Forecast & Price Target
ESLA Analyst Ratings
Bulls say
Estrella Immunopharma is poised to disrupt the field of immunotherapy with its innovative CD19 and CD22-targeted ARTEMIS T-cell therapies, providing a promising treatment option for patients with blood cancers and solid tumors. With the ongoing success of its STARLIGHT-1 study and strong commentary from management, the company is making strides in advancing its clinical program and has extended its operational runway with its recent capital raise. Despite its recent decline, the potential for future partnerships and market opportunities in the field of CAR-T therapy make Estrella Immunopharma a strong long-term investment with a conservative target price of $8.00.
Bears say
Estrella Immunopharma is a clinical-stage biopharmaceutical company with a negative outlook due to concerns about the success of their ARTEMIS T-cell therapy platform. The company's valuation is based on only a 30% probability of success and a 30% discount rate, indicating limited confidence in their potential. While they have entered Phase II with their EB103 treatment, there are concerns about its ability to address limitations of existing CAR-T therapies and the company's cash burn and potential future raises raise further concerns about their long-term prospects.
This aggregate rating is based on analysts' research of Estrella Immunopharma Inc and is not a guaranteed prediction by Public.com or investment advice.
ESLA Analyst Forecast & Price Prediction
Start investing in ESLA
Order type
Buy in
Order amount
Est. shares
0 shares